BG
FOLD

Bellevue Group’s Amicus Therapeutics FOLD Stock Holding History

Bellevue Group’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,735,195
Closed -$153M – 171
2025
Q4 		$153M Buy
+10,735,195
New +$105M 2.9% 11
2019
Q3 		– Sell
-150,000
Closed -$1.87M – 217
2019
Q2 		$1.87M Hold
150,000
– – 0.03% 132
2019
Q1 		$2.04M Buy
+150,000
New +$1.83M 0.11% 108

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Bellevue Group's FOLD Position: Q1 2026 in Review

Bellevue Group sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 10,735,195 shares — an estimated $153M sold.

Bellevue Group first reported a position in FOLD in Q1 2019 and held it in 3 quarters. The position peaked at $153M in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Bellevue Group reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bellevue Group sold 10,735,195 Amicus Therapeutics shares in Q1 2026, an estimated $153M.
  • Bellevue Group first reported a position in Amicus Therapeutics in Q1 2019 and held it in 3 quarters.
  • Bellevue Group's Amicus Therapeutics position peaked at $153M in Q4 2025.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.